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Background: There are few data on the cost-effectiveness of sec-
ond-line chemotherapies for non-small cell lung cancer (NSCLC).
The objective of this phase III, randomized, multicenter, prospective
study was to compare the cost-effectiveness of docetaxel and pem-
etrexed, two widely used drugs.
Methods: We compared, from a payer’s perspective, the directs
costs and effectiveness of docetaxel (75 mg/m2, arm A) and pem-
etrexed (500 mg/m2, arm B) administered every 3 weeks to NSCLC
patients who had progressed after first-line platinum-based chemo-
therapy. Monthly health utilities (based on disease states: respond-
ing, stable or progressive, and grade 3/4 toxicities) were derived
from the literature. Costs were prospectively assessed.
Results: One hundred fifty patients were enrolled between February
2006 and June 2008. The patients in the docetaxel and pemetrexed
arms had similar clinical characteristics and treatment efficacy
(respective objective response rates 10.7% and 12%; median pro-
gression-free survival times 2.8 and 2.5 months; median survival
times 8.0 and 6.4 months, respectively). Grade 3/4 toxicities were
significantly less frequent with pemetrexed (52.0% versus 33.3%,
p  0.02). Docetaxel was associated with lower treatment-period
costs (€9709  €6272 versus €13,436  €6508, p  0.001).
Docetaxel had a more favorable cost-utility ratio than pem-
etrexed. When compared with best supportive care, the cost-
utility was €32,652/quality-adjusted life year for docetaxel and
€40,980/quality-adjusted life year for pemetrexed.
Conclusion: Second-line treatment for NSCLC is more cost-effec-
tive with docetaxel than with pemetrexed. Both strategies have
acceptable cost-effectiveness ratios compared with commonly used
and reimbursed regimens for advanced NSCLC.
Key Words: Non-small cell lung cancer, Second-line chemother-
apy, Pemetrexed, Docetaxel, Cost-effectiveness, Cost-utility.
(J Thorac Oncol. 2011;6: 161–168)
The National Institutes of Health estimated that $89 billionwas spent on cancer care in the United States in 2007, and
that the total economic burden reached $219.2 billion when
indirect costs associated with lost productivity and death were
taken into account. Recent trends suggest that the growth in
cancer spending will accelerate, owing to costly new treat-
ments and the increasing number of cancer patients. Lung
cancer is the second most common malignancy in the United
States and is the leading cause of cancer-related death.1
Non-small cell lung cancers (NSCLC) represent 80% of lung
cancers, and most patients already have advanced or meta-
static disease at diagnosis. Combination chemotherapy is
recommended for patients with good performance status.2
Most patients progress after first-line therapy, and second-
line chemotherapy is recommended for those whose perfor-
mance status remains acceptable. Several agents have been
shown to improve survival in this setting, including docetaxel
and pemetrexed.2–6 Docetaxel improves survival relative to
best supportive care,7 and pemetrexed showed similar effi-
cacy but less toxicity when compared head-to-head with
docetaxel in a phase III randomized trial involving 571
previously treated patients with advanced NSCLC.8 The me-
dian and progression-free survival (PFS) times were, respec-
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tively, 8.3 and 2.9 months with pemetrexed and 7.9 and 2.9
months with docetaxel. Pemetrexed was associated with sig-
nificantly fewer grade 3/4 adverse events (AEs),8 fewer
hospital admissions for AEs, and fewer toxic deaths.8
However, very few data are available on the cost-
effectiveness of these two drugs. All pharmacoeconomic
studies published to date are retrospective and model-
based.9–12 A recent international expert panel has stated that
“prospective pharmacoeconomic analysis of second-line
treatment would be useful to inform clinical practice in this
setting.”13
The principal objective of this study was to compare the
cost-effectiveness of second-line docetaxel and pemetrexed
therapy in NSCLC patients. Secondary end points were the
responses rates, PFS, overall survival, and survival without
major clinical toxicity.
PATIENTS AND METHODS
Patient Selection and Clinical Evaluation
This phase III, randomized, prospective, multicenter
study included patients aged 18 years and older, with at least
one measurable lesion, histology-proven stage IIIb or IV
NSCLC, good performance status (Eastern Cooperative On-
cology Group score 0–2), and progressive disease after a
single cisplatin-based chemotherapy regimen for metastatic
disease; one previous additional neoadjuvant, adjuvant, or
neoadjuvant plus adjuvant regimen was allowed. Patients
with symptomatic brain metastasis; grade 3 or 4 peripheral
neuropathy; weight loss of 10% or more during the previous
6 weeks; uncontrolled pleural effusion; upper vena cava
syndrome; previous docetaxel or pemetrexed therapy; non-
steroidal anti-inflammatory drug dependency; or altered he-
matologic, kidney, or hepatic function were excluded. The
patients were randomized, after stratification for performance
status (0–1 versus 2) and the number of metastatic sites (1
versus 1), to receive one dose every 21 days of either
pemetrexed (500 mg/m2 as a 10-minute intravenous infusion)
plus vitamin B12 injections and oral folic acid supplementa-
tion or docetaxel (75 mg/m2 as a 1-hour intravenous infu-
sion). The protocol was approved by Limoges Hospital ethics
committee.
Cycles were repeated until unacceptable toxicity or
disease progression occurred, or until the patient or inves-
tigator requested treatment discontinuation. Granulocyte
colony-stimulating factor (G-CSF) primary prophylaxis
was not allowed, but G-CSF could be used to treat neu-
tropenia or to prevent neutropenia in patients who had
neutropenia during a previous cycle. Comprehensive base-
line assessment included laboratory tests and imaging
studies. Hematological analyses were performed weekly
and blood chemistry analyses on days 1 and 8 of each
cycle. Toxicity was rated before each cycle by using the
National Cancer Institute Common Toxicity Criteria (CTC),
version 2. Tumor size was measured every three cycles (in
keeping with standard French practices in second-line set-
tings) by an independent panel using RECIST criteria.
Economic Assessment
First resource consumption was assessed prospectively
from the case report forms throughout second-line chemo-
therapy. This analysis included the chemotherapy drugs,
supportive treatment (recombinant human erythropoietin, an-
tiemetics, growth factors, antibiotics, management of adverse
effects, etc.), hospitalization for any reason, and medical
transport. All the volumes were collected and added together,
but only grade 3/4 AE management costs were taken into
account.
Second costs were derived from national tariffs for
diagnosis-related groups and national fees for ambulatory
care, provided by the French Ministry of Health and the
national health insurer.14,15 Volumes, unit prices, and tariff
sources are shown in Table 1.
Third, during the treatment period, all the data were
prospectively recorded. Costs incurred after the period of
second-line chemotherapy (remission period or disease pro-
gression period) were derived from a representative French
nationwide sample of 428 patients, using chart review to
assess the mean direct monthly cost of the first 18 months of
NSCLC patient management.16 Specifically, the costs in-
cluded outpatient and inpatient services, care provision at
skilled nursing facilities, outpatient and inpatient drugs and
other medications, nursing care organization, home health
visits (including medications), and durable medical equip-
ment. Assuming a yearly increment of 3%, 1 month of
management costs €217 (2009 values) during the remission
phase and €2324 (2009 values) during the terminal phase.
Utility (Quality of Life) Assessment
Health state preference scores or utilities measure the
strength of an individual’s preferences for specific outcomes
under conditions of uncertainty and are used to measure
health-related quality of life (HRQL). After randomization,
each patient was classified in one of the following mutually
exclusive and exhaustive states each month: responding on
chemotherapy, with or without grade 3/4 AEs; stable, with or
without grade 3/4 AE; progression, with or without grade 3/4
AE; and death. The utilities were derived from UK society-
based utility values for different stages of NSCLC and dif-
ferent grade 3/4 toxicities commonly associated with chemo-
therapy (Table 2).17 Thus, we calculated the quality-adjusted
life year (QALY) value per patient, from randomization to
death or censor date, and QALY per treatment arm.
Costs of survival and utility were used to calculate, for
each chemotherapy arm, a cost per life year ratio and a cost
per QALY and to compare the values thus obtained between
the two arms.
Sensitivity Analyses
The uncertainty and robustness of the model were
evaluated in one-way sensitivity analyses, by varying the cost
of chemotherapy and the values of utilities, the percentage of
AEs hospitalization, and the percentage of patients treated by
G-CSF while keeping the other parameters constant, over a
range of likely values derived from confidence intervals or
reasonable ranges.
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Statistical Analysis
The required number of patients was determined from
published data, with a type 1 risk of 5% and a power of 1 
 at 80%. The number of patients required to show a 10%
cost difference favoring one or other strategy was 72 per arm
or a total of 150 patients when probable losses to follow-up
were taken into account. Tumor response rates and the fre-
quency of AEs were compared between the arms by using
Fisher’s exact test. All the responses were evaluated by an
investigator panel. Quantitative variables were compared us-
ing Student’s t test or the Wilcoxon test when the data were
not normally distributed. The Kaplan-Meier and Cox meth-
ods were used for time-to-event analyses. Overall survival
was censored at the date of the last follow-up visit for patients
who were still alive. We also calculated survival without the
most clinically important grade 3/4 toxicities (neutropenia
lasting more than 5 days; febrile neutropenia; and docu-
mented infections related to neutropenia, anemia, thrombo-
cytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and
neurosensory events), which is defined as the time from
randomization to the first grade 3 or 4 toxicity or death.18
Costs were estimated using nonparametric bootstrap methods
(10,000 bootstrap resamples were generated). SAS software
version 9 (SAS Inc., Cary NC) and Epi-Info V6.04 (CDC,
Atlanta, GA) were used for statistical analyses.
RESULTS
Between February 2006 and June 2008, 150 patients
recruited in 27 centers were randomized to receive pem-
etrexed every 3 weeks plus vitamin B12, 1000 g every 9
weeks and folinic acid, 0.4 mg daily (n  75), or docetaxel
every 3 weeks (n  75). The censor date was August 31,
2009. Figure 1 shows the study flow chart. Baseline charac-
teristics were similar and well balanced across the treatment
TABLE 1. Description of Some Recorded Data for Economical Analysis, with Unit Price and Tariff Sources
Categories Volumes Unit Price Origin
Transportation Car €11.73a  €0.83 per km
Ambulance €49.33a  €2.12 per km
Chemotherapeutic drugs Docetaxel €10.7/mg Health Ministry15
Pemetrexed €2.9/mg
Granulocyte colony-stimulating factor Lenograstim and filgrastim €115 and €119 per injection Health Ministry15
Procedures Chest X-ray €21.28 16th version14
Chest CT scan €25.27
Lung scintigraphy €176.85
Bronchoscopy €86
Dorsal spine MRI €69
Brain CT scan €25.27
Brain MRI €69
Drug administrationb Outpatient €417.00 DRG 10th version15
Inpatient 1 night €588.00
Inpatient 2 nights €1809.00
Follow-upb Outpatient €588.00 DRG 10th version15
Adverse event admissionb
(examples)
Poor performance status €4158.21 DRG 10th version15
Neutropenia/anemia €3930.08
Breathlessness €3450.43
Fever €4015.61
Dehydration €3563.22
Transfusion (outpatient) €668.54
Consultation Ambulatory €23.00 16th version14
a Average of four French areas.
b Average of 2006, 2007, and 2008 tariffs.
MRI, magnetic resonance imaging; CT, computed tomography; DRG, Diagnosis-related Groups.
TABLE 2. NSCLC Patients Treated with Second-Line
Chemotherapies: Utility Values for Health States After
Randomization (Derived from Nafees et al.17)
Health State Values
Responding without grade 3/4 toxicities 0.712
Responding with grade 3/4 toxicities 0.666
Stable without grade 3/4 toxicities 0.626
Stable with grade 3/4 toxicities 0.580
Progressive without grade 3/4 toxicities 0.473
Progressive with grade 3/4 toxicities 0.460
NSCLC, non-small cell lung cancer.
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arms, with no statistically significant differences in age,
gender, performance status, the proportion of stage IV dis-
ease, or histology (Table 3). There was no difference in the
time between the end of first-line chemotherapy and the
beginning of second-line chemotherapy (5.8  6.1 months in
the docetaxel arm and 5.1  5.9 months in the pemetrexed
arm). On average, the patients received 3.7  1.9 cycles of
docetaxel (range, 1–6 cycles) and 3.6  1.8 cycles of pem-
etrexed (range, 1–7 cycles), with no difference in dose inten-
sity (data not shown). Efficacy was similar in the two arms,
with no significant difference in the tumor response rate or
the PFS time (Table 3). The median overall survival time was
also similar (8.0 months with docetaxel and 6.4 months with
pemetrexed), and the 1- and 2-year overall survival rates
were, respectively, 32.0% and 11.7% with docetaxel and
27.1% and 9.8% with pemetrexed (Figure 2). Patients treated
with pemetrexed had significantly fewer episodes of throm-
bocytopenia, hair loss, and nausea of CTC grade 1/2 (data not
shown) and significantly fewer CTC grade 3/4 toxicities (p
0.02), including less neutropenia (34.7% and 8.0%, p 
0.001, with docetaxel and pemetrexed, respectively; Table 4).
There was no difference in the frequency of hospitalization
for AEs (0.44  0.84 versus 0.52  0.89 hospital admissions
per patient with docetaxel and pemetrexed, respectively).
Patients treated with docetaxel required significantly more
supportive care (G-CSF, red cell transfusions, and recombi-
nant human erythropoietin) than patients treated with pem-
etrexed (19.2% versus 2.6%, p  0.001). There was no
difference in the median survival time without selected grade
3/4 toxicities or death (2.7 and 3.5 months with docetaxel and
pemetrexed, respectively; Figure 3). There was also no dif-
ference in QALY (Table 5). Docetaxel therapy was signifi-
cantly less costly during the treatment periods (€9709 
€6272 versus €13,436  €6508, p  0.001) and during the
overall study period (€13,714  €7387 versus €16,802 
€7852 [2009 values], p  0.022). Docetaxel was dominant
versus pemetrexed with an average total cost difference of
€3,182 (€5,158; €1096) and an average utility differ-
ence of 0.14 (1.34; 1.63). Figure 4 shows the distribution of
the two values according to the bootstrap simulation. When
compared with best supportive care, the costs per life year
and per QALY were significantly lower in the docetaxel arm
(€15,545 versus €22,798, p  0.01, and €32,652 versus
€40,980, p  0.003).
Sensitivity analyses (Table 6) showed that the cost of
pemetrexed therapy would have to fall by 30% to balance the
QALY values in the two arms. Varying the rate of G-CSF
administration in the docetaxel arm, the rate of hospitaliza-
tion (according to the results of Hanna et al.,8 23.9% for
docetaxel and 7.9% for pemetrexed) or utility values by
10% did not affect the results.
FIGURE 1. Study flow chart.
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DISCUSSION
In this randomized, multicenter, prospective study
comparing the cost-effectiveness of docetaxel and pem-
etrexed, two second-line chemotherapies widely used for
NSCLC, efficacy was similar with the two drugs, but pem-
etrexed was associated with significantly less overall grade
3/4 toxicity. Compared with pemetrexed, docetaxel was as-
sociated with significantly lower treatment-period costs and
total management costs and a better ratio of cost per QALY
(€32,652 versus €40,980, p 0.003). In terms of efficacy and
toxicity, the results of this study are similar to those published
elsewhere. In the pivotal study comparing docetaxel with best
supportive care,7 median overall survival was 7.0 months and
the 1-year survival rate was 29%, compared with 8 months
and 32% in our study. Likewise, the 1-year survival rate in
the docetaxel arm of the TAX320 trial was 32%.19 Neutro-
penia and febrile neutropenia were the main toxicities re-
ported in this trial. Pemetrexed 500 mg/m2 was compared
with docetaxel 75 mg/m2 in a phase III face-to-face trial.8 The
response rate, PFS, median overall survival, and 1-year sur-
vival with docetaxel and pemetrexed were, respectively,
8.8% and 9.1%, 2.9 and 2.9 months, 7.9 and 8.3 months, and
29.7% in both arms. As in our study, patients receiving
docetaxel experienced significantly higher rates of neutrope-
nia, severe neutropenia, and febrile neutropenia. Finally, in a
recent review of phase III trials of second-line NSCLC
chemotherapy,5 the median objective response rate was 6.8%
and the median overall survival time was 6.6 months—values
very similar to those observed in our study.
Patients who experience disease progression during or
after first-line treatment for advanced NSCLC have limited
life expectancy.5 Quality of life is often compromised by
disease-related symptoms, residual toxicity of prior chemo-
therapy, and comorbidity. Second-line treatment should pro-
vide symptom palliation, optimize quality of life, and in-
crease survival.
There are few published data on quality of life or
utilities associated with second-line NSCLC chemotherapies.
Pujol et al.18 retrospectively compared the time from random-
ization to the first occurrence of most clinically important
grade 3/4 toxicities or death in the prospective phase III study
comparing pemetrexed and docetaxel.8 As in our study,
patients treated with pemetrexed had significantly fewer CTC
grade 3/4 toxicities (p  0.001). The median survival times
and 6-month survival rates without grade 3/4 toxicity in
patients treated with pemetrexed and docetaxel were, respec-
tively, 3.5 and 2.7 months and 25.7% and 10.1%. The
respective 12-month survival rates without grade 3/4 toxicity
were 15.9% and 11.4%. Regarding the burden of NSCLC on
HRQL, little information is available on the preferences of
patients or society with respect to disease states.20–23 Trippoli
et al.,24 reporting utility and HRQL data (based on the SF-36
and EQ-5D questionnaires) for 95 NSCLC patients, showed
that HRQL was significantly worse in patients with metastatic
NSCLC. We used the results of Nafees et al.,17 who adapted
existing health state descriptions in metastatic breast cancer,
to describe our patients receiving second-line treatment for
NSCLC. Each health state describes the symptom burden of
disease and its impact on different functions. The disutility
related to each disease state and to toxicity was estimated and
combined to obtain health state values. There are also few
published studies on second-line treatment costs in advanced
NSCLC. Available pharmacoeconomic studies are based on
retrospective models and have several limitations. Using data
from the pivotal study comparing docetaxel and best support-
ive care (BSC) from the perspective of the Canadian public
healthcare system, limited to direct medical costs, Leighl et
al.9 found an incremental survival benefit of 2 months over
TABLE 3. Patient Characteristics and Efficacy of Docetaxel
and Pemetrexed
Patients’ Characteristics
Docetaxel:
Arm A
(n  75)
Pemetrexed:
Arm B
(n  75)
Median age (yr, 95% CI) 59.4  8.3 58.3  8.7
Gender (male, %) 64 (85.3%) 62 (82.7%)
ECOG PS (0 or 1, %) 70 (93.3%) 71 (94.7%)
Stage IV (n, %) 59 (78.7%) 62 (82.7%)
Histology
Squamous (n, %) 23 (30.7%) 18 (24%)
Nonsquamous (n, %) 52 (69.3%) 57 (76%)
Time since first-line
chemotherapy (mo, SD)
5.8  6.1 5.1  5.9
3 mo (%) 50% 45%
Mean cycles of first-line
chemotherapy (SD)
4.5  2.5 4.4  2.1
Mean cycles of second-line
chemotherapy (SD)
3.7  1.9 3.6  1.8
Response rates
Not assessable 16 (21.3%) 20 (26.7%)
Progressive disease 30 (40%) 26 (34.6%)
Stable disease 21 (28%) 20 (26.7%)
Objective response 8 (10.7%) 9 (12%)
PFS (mo, 95% CI) 2.8 (2.2–4.2) 2.5 (2.1–3.9)
Median survival (mo, range) 8 (5.12–10.4) 6.4 (4.8–8.4)
1-yr survival (%, SD) 32  5 27.1  5.2
2-yr survival (%, SD) 11.7  4 9.8  3.6
ECOG PS, Eastern Cooperative Oncology Group performance status; CI, confi-
dence interval; PFS, progression-free survival.
FIGURE 2. Overall survival in the two arms.
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BSC and an incremental cost-effectiveness of docetaxel of
CaD $31,776 (1999 values) per life year gained (LYG) versus
BSC. This cost-effectiveness was most sensitive to changes
in mean survival (20%) and ranged from CaD $18,374 to
117,434 per LYG. Using data from the same randomized
trial, and focusing on direct medical costs limited to drug
acquisition and administration, Holmes et al.10 found that,
TABLE 4. Grade 3 and 4 Toxicities in the Two Arms
Grade 3 and 4 Toxicities
Docetaxel (n  75) Pemetrexed (n  75)
pNo. of Events No. of Patients (%) No. of Events No. of Patients (%)
Neutropenia 45 26 (34.7) 16 6 (8) 0.001
Thrombocytopenia 1 1 (1.3) 5 5 (6.7) NS
Anemia 1 1 (1.3) 9 5 (6.7) NS
Infection 5 4 (5.3) 3 3 (4) NS
Renal toxicity — — 1 1 (1.3) NS
Hepatic toxicity 3 2 (2.7) 9 1 (1.3) NS
Fatigue 19 12 (16) 8 6 (8) NS
Hair loss 10 4 (5.3) — —
Peripheral neuropathy 2 2 (2.7) 2 1 (1.3) NS
Nausea—vomiting 2 2 (2.7) 3 2 (2.7) NS
Pain 7 6 (8) 6 4 (5.3) NS
Other 4 3 (4) 2 2 (2.7) NS
Total 99 39 (52) 64 25 (33.3) 0.02
2 test or Fisher’s exact test.
FIGURE 3. Survival without grade 3/4 adverse events and
death.
TABLE 5. Costs (2009 Euros) and Cost-Effectiveness of
Docetaxel and Pemetrexed
Docetaxel
(n  75)
Pemetrexed
(n  75) p
Costs (2009 euros)
Treatment periods (drugs,
administration,
transportation,
and adverse events)
9709  6272 13,436  6508 0.001
Follow-up 782  1568 731  1512 NS
Palliative care 3223  3479 2634  3227 NS
Total €13,714  €7387 €16,802  €7852 0.022
QALY 0.42  0.4 0.41  0.39 NS
Cost-effectiveness
Cost per LYG 15,545 22,798 0.01
Cost per QALY 32,652 40,980 0.003
LYG, life year gained; QALY, quality-adjusted life years.
FIGURE 4. Bootstrap of cost and utility differences (A and B
areas in favor of pemetrexed, C and D areas in favor of do-
cetaxel). The results favored docetaxel arm.
TABLE 6. Sensitivity Analysis
Variable
Cost per QALY
p
Docetaxel
(n  75)
Pemetrexed
(n  75)
Cost of pemetrexed: 30% 32,913 34,403 NS
Rate of G-CSF use in
docetaxel arm (50%)
34,218 40,980 0.001
Hospitalization rates from
the study by Hanna et al.8
39,790 45,588 0.01
Values of utilities: 10% 36,570 45,823 0.001
Values of utilities: 10% 29,921 37,407 0.001
QALY, quality-adjusted life years; G-CSF, granulocyte colony-stimulating factor.
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from the perspective of the UK National Health Service, the
use of docetaxel resulted in a survival benefit of 3.8 months
with a cost-effectiveness of £13,863 per LYG (2000–2001
values). However, this study did not consider AEs or quality
of life, which were drivers of both QALY and costs in our
analysis. Pavlakis et al.12 assessed the cost-effectiveness of
pemetrexed relative to docetaxel. Rather than focusing on
direct medical costs, they chose the reduction in toxicity-
related hospitalization as the outcome measure. The incre-
mental cost of avoiding one toxicity-related hospital admis-
sion was US $15,754 (year of value not stated), suggesting an
advantage of pemetrexed.
Our results are in line with those of a recently published
model-based analysis comparing the economic value of do-
cetaxel, pemetrexed, and erlotinib in a cohort of patients with
refractory advanced-stage NSCLC.25 The authors developed
a decision analytic model to evaluate, from the US payer’s
perspective, the incremental costs and QALY of these three
strategies, based on efficacy and AE rates in published clin-
ical trials, as well as the work of Nafees et al. on utilities and
on publicly available cost sources. They found that treatment
with erlotinib, docetaxel, and pemetrexed yielded 0.42, 0.41,
and 0.41 QALY, compared with 0.42  0.4 and 0.41  0.39,
respectively, for docetaxel and pemetrexed in our study. Total
costs were US $37,000, 39,100, and 43,800 for erlotinib,
docetaxel, and pemetrexed, respectively, compared with
€13,714  €7387 and €16,802  €7852, respectively, for
docetaxel and pemetrexed in our study. The costs of periods
of progression were markedly different: US $24,017 for the
three strategies in the study by Carlson et al.,25 compared
with €3223  €3479 and €2634  €3227, respectively, for
docetaxel and pemetrexed in our study. In Carlson’s model-
based study,25 one-way sensitivity analyses indicated that the
primary drivers of variations in total costs were the time spent
in the progression-free health state, the treatment duration,
and drug costs. The primary driver of the QALY difference
was the time spent in the progression-free health state.
Our study has certain limitations. First, costs were
identified prospectively only during the active treatment pe-
riods, whereas management costs after the end of chemother-
apy were derived from a national database. Second, our
analysis was limited to direct lung cancer-related medical
costs: indirect costs such as lost productivity and caregiver
costs were not included. Third, the expression of utilities
reflects the value from the point of view of society rather than
that of the patients concerned. Finally, we did not analyze the
cost-effectiveness of erlotinib, an oral epidermal growth fac-
tor receptor tyrosine kinase inhibitor that has been shown to
improve survival among patients with advanced NSCLC who
have previously received one or more chemotherapy regi-
mens.26,27 Several recent model-based pharmacoeconomic
studies25,28 suggest that erlotinib 150 mg/d is a cost-saving
second-line option relative to approved second-line intrave-
nous chemotherapies such as docetaxel and pemetrexed.
CONCLUSION
Second-line NSCLC chemotherapy is more cost-effec-
tive with docetaxel than with pemetrexed, when they are
directly compared. A head-to-head prospective trial is now
needed to compare the cost-effectiveness of these chemother-
apies and erlotinib.
APPENDIX: THE GFPC 0506 TEAM
A. Vergnene`gre, F. Bonnaud, B. Melloni, Ch. Decroi-
sette, F. Touraine (Limoges), F. Blanchon, C. Locher, M.
Grivaux (Meaux), V. Garcia, F. Lebargy (Reims), G. Robi-
net, S. Gouva, R. Descourt (Brest), P. Thomas (Gap), J.A.
Silvani (Bastia), C. Gimenez, F. Barle´si, Ph. Astoul (Mar-
seille), H. Le Caer (Draguignan), P. Fournel, S. Bayle (Saint-
Etienne), P. Bombaron (Mulhouse), M. Pe´rol, E. Biron, J.C.
Gue´rin, D. Arpin (Lyon), L. Falchero (Villefranche sur Sa-
oˆne), J. Letreut, R. Poirier, F. Mouysset (Aix-en-Provence),
J.M. Chavaillon (Antibes), H. Be´rard (Toulon), J.M. Verne-
joux, A. Taytard (Pessac), S. Kasseyet (Salon de Provence),
D. Paillotin, J.F. Muir (Rouen), L. Thiberville, S. Bota, G.
Nouvet (Rouen), J.Y. Delhoume (Pe´rigueux), H. Le´na, C. Bel-
leguic, P. Delaval (Rennes), N. Rossignol (Macon), E.
Bouchaert, J. Crequit (Beauvais), S. Hominal (Annecy), F.
Chomy (Bordeaux), J.B. Auliac (Mantes-la-Jolie), C. Chouaïd,
M. Baud (Paris), H. Jullian (Martigues), P.J. Souquet, L.
Ge´rinie`re (Lyon), B. Etienne-Mastroianni, J.F. Cordier
(Lyon), S. Chouabe (Charleville Me´zie`res), Th. Urban, Y. Le
Guen, Th. Jeanfaivre, J. Hureaux (Angers), Ph. David, C.
Vincent (Elbeuf), I. Monnet (Cre´teil), V. Grangeon (Roanne),
F. Grassin, M. Andre´ (Brest), L. Bigay-Game, M.-C. Pujazon
(Toulouse), N. Roche, F. Giraud (Paris), G. Oliviero
(Longjumeau), J.F. Berdah (Toulon), S. Larive´ (Auxerre),
and C. Dujon (Le Chesnay).
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